Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · The Vita Coco (COCO)

Vita Coco adds Shelley Broader to board and names Charles van Es chief commercial officer

Neutral Impact 3 of 5 leadership Written later

Vita Coco's board increased its size from nine to ten directors and appointed Shelley Broader as a Class II director on January 7, 2026. The Board also appointed Charles van Es as Chief Commercial Officer, effective January 1, 2026, with no change to his compensation. The filing contains no financial results or guidance, so the changes are governance and management updates rather than a direct measure of business performance.

Key points

  • Shelley Broader appointed to the Board on January 7, 2026, filling a newly created seat, which expanded the Board from nine to ten directors
  • Charles van Es named Chief Commercial Officer effective January 1, 2026; he will lead global commercial strategy and market development while continuing to oversee the US market
  • Committee assignments for Ms. Broader have not been determined; the company will file an 8-K amendment once they are set

The filing

CompanyThe Vita Coco (COCO)
Form8-K, current report
Filed with the SECJan 8, 2026, 4:20 PM ET
Accession number0001628280-26-001348

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on January 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.